Affiliations 

  • 1 Renal Medicine, Royal Prince Alfred Hospital, Sydney, NSW, Australia
  • 2 Nephrology Department, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia
Transpl Int, 2021 12;34(12):2431-2441.
PMID: 34626503 DOI: 10.1111/tri.14132

Abstract

Delayed graft function (DGF) after kidney transplantation is associated with inferior outcomes and higher healthcare costs. DGF is currently defined as the requirement for dialysis within seven days post-transplant; however, this definition is subjective and nonspecific. Novel biomarkers have potential to improve objectivity and enable earlier diagnosis of DGF. We reviewed the literature to describe the range of novel biomarkers previously studied to predict DGF. We identified marked heterogeneity and low reporting quality of published studies. Among the novel biomarkers, serum NGAL had the greatest potential as a biomarker to predict DGF, but requires further assessment and validation through larger scale studies of diagnostic test performance. Given inadequacies in the dialysis-based definition, coupled with the high incidence and impact of DGF, such studies should be pursued.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.